

type of report	Current report
number	85/2012
company	PHARMENA

#### **Establishing the issue price of series D shares**

The Management Board of PHARMENA S.A. informs that on 17<sup>th</sup> December 2012, a meeting of Supervisory Board took place. Pursuant to resolution no. 4 adopted on 21<sup>st</sup> August 2012 during Extraordinary General Meeting of Pharmena S.A. on the Company's share capital increase through issue of series C bearer shares through private placement with pre-emptive rights for hitherto shareholders and the change to the Company's Articles of Association, the Management Board, having obtained the consent of the Supervisory Board, established the issue price of series D ordinary bearer shares at 7.50 PLN (say: seven PLN 50/100) per 1 share.

The goal of the issue of series D shares is to obtain funds for phase II ("Proof of Concept") clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA.

The information is made public due to the fact that the goal of the public offering of series D shares with pre-emptive rights is to obtain funds for phase II clinical trials of anti-atherosclerosis medicinal product 1-MNA, the results of which may have significant influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

#### **Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board